Drug Trial Radar · NCT06810505
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Feb 13, 2025
Primary completion
Mar 2031
Study completion Mar 2031
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world. Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks. Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.
Conditions
- Chronic Migraine
Interventions
AtogepantDrug
Oral tablet
Placebo for AtogepantDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 16 weeks
- Change From Baseline in Mean Monthly Migraine DaysTime frame: Baseline (Week 0) through Week 12
Locations
66 sites in 11 countries. Site status is shown where the registry gives one.
Rehabilitation and Neurological Services /ID# 270782
Huntsville, Alabama · Recruiting
Preferred Research Partners - Fayetteville /ID# 270419
Fayetteville, Arkansas · Completed
Preferred Research Partners /ID# 270389
Little Rock, Arkansas · Recruiting
Advanced Research Center /ID# 270257
Anaheim, California · Recruiting
Neuro Pain Research Center /ID# 271048
Fresno, California · Recruiting
Alliance for Research Alliance for Wellness /ID# 270398
Long Beach, California · Recruiting
Excell Research /ID# 270258
Oceanside, California · Recruiting
Lumos Clinical Research Center /ID# 270582
San Jose, California · Recruiting
Sunwise Clinical Research /ID# 270431
Walnut Creek, California · Recruiting
Northwest Florida Clinical Research Group, LLC /ID# 270833
Gulf Breeze, Florida · Recruiting
Auzmer Research /ID# 271158
Lakeland, Florida · Completed
My Preferred Research /ID# 270312
Miami, Florida · Recruiting
Encore Medical Research - Weston /ID# 271139
Weston, Florida · Recruiting
Pediatric Neurology & Epilepsy Center Of Central Florida - Winter Park /ID# 275263
Winter Park, Florida · Recruiting
Deaconess Midtown Hospital /ID# 270572
Evansville, Indiana · Recruiting
Michigan Headache & Neurological Institute /ID# 270942
Ann Arbor, Michigan · Recruiting
Proven Endpoints LLC /ID# 270269
Ridgeland, Mississippi · Recruiting
Cct Research - Papillion Research Center /ID# 270393
Papillion, Nebraska · Recruiting
Healthy Perspectives - Innovate Mental Health Services /ID# 270847
Nashua, New Hampshire · Recruiting
Dent Neurologic Institute - Amherst /ID# 270260
Amherst, New York · Recruiting
Headache Wellness Center /ID# 270568
Greensboro, North Carolina · Completed
The Children's Hospital of Philadelphia /ID# 270842
Philadelphia, Pennsylvania · Recruiting
Frontier Clinical Research - Scottdale /ID# 270854
Scottdale, Pennsylvania · Recruiting
Frontier Clinical Research - Smithfield /ID# 270849
Smithfield, Pennsylvania · Recruiting
Access Clinical Trials Inc /ID# 270280
Nashville, Tennessee · Recruiting
UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577
Austin, Texas · Recruiting
Earle Research /ID# 270424
Houston, Texas · Recruiting
Clinpoint Trials /ID# 270261
Waxahachie, Texas · Recruiting
Pantheon Clinical Research /ID# 270259
Bountiful, Utah · Recruiting
Alpine Research Organization - Clinton /ID# 276527
Clinton, Utah · Recruiting
Highland Clinical Research /ID# 270281
Salt Lake City, Utah · Recruiting
Frontier Clinical Research - Kingwood /ID# 271053
Kingwood, West Virginia · Recruiting
London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270659
London, Ontario, Canada · Recruiting
McGill University Health Centre - Glen Site /ID# 270662
Montreal, Quebec, Canada · Completed
Herlev Hospital /ID# 270482
Herlev, Capital Region, Denmark · Recruiting
Regionshospitalet Godstrup /ID# 270481
Herning, Central Jutland, Denmark · Recruiting
Semmelweis Egyetem /ID# 271219
Budapest, Hungary · Recruiting
Rozsavolgyi Rendelo-Ceba Bt. /ID# 271500
Budapest, Hungary · Recruiting
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 270756
Milan, Milano, Italy · Recruiting
Ospedale Pediatrico Bambino Gesu /ID# 270759
Rome, Roma, Italy · Recruiting
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.